Tele-PancFit: A Multi-site Trial of Video-based Strengthening Exercise Prehabilitation for Patients With Resectable Pancreatic Cancer
Phase 3
Recruiting
- Conditions
- Pancreatic Cancer
- Interventions
- Other: Enhanced Usual CareBehavioral: Tele-supervised resistance exercises
- First Posted Date
- 2023-05-01
- Last Posted Date
- 2024-06-25
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 120
- Registration Number
- NCT05836870
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
The Use of Cannabis (Marijuana) and Cannabidiol (CBD) Among Cancer Patients: a Pilot Study
Active, not recruiting
- Conditions
- Cancer
- Interventions
- Behavioral: Cannabis (Marijuana)Behavioral: Cannabidiol (CBD)
- First Posted Date
- 2023-05-01
- Last Posted Date
- 2024-10-01
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 100
- Registration Number
- NCT05836857
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Sexual Dysfunction in Palliative Care Patients: An Assessment of Patient's Perspective
Completed
- Conditions
- Sexual Dysfunction
- Interventions
- Behavioral: Patient's Perspective
- First Posted Date
- 2023-05-01
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 104
- Registration Number
- NCT05837117
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
A Comparison of Healthcare Provider and Caregiver Perception of Discomfort in Advanced Cancer Patients Who Have a Hypoactive Delirium
Recruiting
- Conditions
- Hypoactive Delirium
- Interventions
- Behavioral: Healthcare ProviderBehavioral: Caregiver Perception
- First Posted Date
- 2023-05-01
- Last Posted Date
- 2024-03-27
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 100
- Registration Number
- NCT05837039
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
A Phase Ib Trial of Azacitidine, Venetoclax and Allogeneic NK Cells for Acute Myeloid Leukemia (ADVENT-AML)
Phase 1
Recruiting
- Conditions
- Acute Myeloid Leukemia
- Interventions
- First Posted Date
- 2023-04-28
- Last Posted Date
- 2024-12-09
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 32
- Registration Number
- NCT05834244
- Locations
- 🇺🇸
M.D. Anderson Cancer Center, Houston, Texas, United States
Phase I Trial Testing the Safety and Tolerability of Chemoradiation Followed by Chemotherapy + Dostarlimab for Stage IIIC, Node Positive, Endometrial Cancer
Phase 1
Recruiting
- Conditions
- Endometrial Cancer
- Interventions
- First Posted Date
- 2023-04-19
- Last Posted Date
- 2024-06-04
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 21
- Registration Number
- NCT05819892
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Window-of-Opportunity Trial of Ulixertinib for MAPK-Activated Low-Grade Gliomas in Adults
- First Posted Date
- 2023-04-07
- Last Posted Date
- 2024-11-11
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 20
- Registration Number
- NCT05804227
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Phase I Study of TH1 Dendritic Cell Immunotherapy for the Treatment of Cutaneous Angiosarcoma
Phase 1
Withdrawn
- Conditions
- Angiosarcoma
- Interventions
- Drug: PaclitaxelBiological: mRNA plus Lysate-loaded Dendritic Cell VaccineDrug: PEGYLATED-INTERFERON ALPHA-2ADrug: Filgrastim
- First Posted Date
- 2023-04-05
- Last Posted Date
- 2024-11-08
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 24
- Registration Number
- NCT05799612
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Multi-site Feasibility and Acceptability of a Faith-based Mind-body Intervention for Black Adults
Not Applicable
Recruiting
- Conditions
- PsychosocialMind-body
- Interventions
- Behavioral: Harmony & Health InterventionBehavioral: Attention ControlDevice: Fitbit
- First Posted Date
- 2023-03-30
- Last Posted Date
- 2024-11-26
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 100
- Registration Number
- NCT05791981
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Post-Transplant Maintenance Therapy with Isatuximab Plus Lenalidomide for High-Risk Multiple Myeloma Patients
- First Posted Date
- 2023-03-20
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 61
- Registration Number
- NCT05776979
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
© Copyright 2025. All Rights Reserved by MedPath